SCHEMBL4498670

SCHEMBL4498670

O=C(NCc1cccnc1)c1ccc2c(c1)ncn2-c1cccc(O)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.53
TDP1 Q9NUW8 1/20 0.52
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
HPGD P15428 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.48
USP2 O75604 1/20 0.48
ALDH1A1 P00352 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
MAPK1 P28482 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
PIK3CA P42336 1/20 0.47
PSMD14 O00487 1/20 0.47
STAMBP O95630 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
TSHR P16473 1/20 0.47
BLM P54132 1/20 0.47
NAMPT P43490 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4499742 0.90 TP53 (0.59) TP53TDP1KMT2AMEN1L3MBTL1
SCHEMBL1381717 0.90 LMNA (0.55) TP53TDP1KMT2AMEN1HPGD
SCHEMBL2338339 0.90 POLB (0.57) TP53TDP1KMT2AMEN1HPGD
SCHEMBL4501697 0.90 TP53 (0.52) TP53TDP1KMT2AMEN1HPGD
SCHEMBL16082503 0.90 TP53 (0.67) TP53TDP1KMT2AMEN1HPGD
SCHEMBL2337525 0.90 GABRA1 (0.58) TP53TDP1KMT2AMEN1HPGD
SCHEMBL1377354 0.89 TP53 (0.51) TP53TDP1KMT2AMEN1HPGD
Hydrochloric Acid SCHEMBL4498242 0.89 TP53 (0.51) TP53TDP1KMT2AMEN1HPGD
SCHEMBL2336963 0.89 TP53 (0.51) TP53TDP1KMT2AMEN1HPGD
SCHEMBL4506055 0.87 LMNA (0.54) TP53TDP1KMT2AMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7521448-B2 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-04-21 US disclosed
US-7521448-B2 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-04-21 US disclosed
US-7521448-B2 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-04-21 US disclosed
US-7419995-B2 N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library OSI PHARMACEUTICALS, INC. (US) 2008-09-02 US disclosed
US-7419995-B2 N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library OSI PHARMACEUTICALS, INC. (US) 2008-09-02 US disclosed
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. 2006-08-24 US disclosed
EP-1664021-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI Pharmaceuticals, Inc. (US) 2006-06-07 EP disclosed
WO-2005021531-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors KIT, CHUK, TNNI3K TP53 119/4885TDP1 3696/4885KMT2A 518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.